News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
ViTToria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of its VIPER-101 T-Cell Therapy
ViTToria has dosed the first patient in its Phase 1 clinical trial for VIPER-101.
āshibio Moves Forward with Clinical Trial
āshibio announced the dosing of the first participant in its Phase 2/3 clinical trial for its lead candidate, andecaliximab.
Cogwear Featured as a Startup to Watch in 2025
Cogwear was listed as one of PHL Inno’s Startups to Watch.
Interius Ranks in Top Ten of Capital Raises by Philadelphia Startups in 2024
Interius was recognized in the Philadelphia Business Journal’s “PHL Inno 2024 in Review” as one of the top Philadelphia-area startups raising capital last year.
Gemma Biotherapeutics and Franklin Biolabs Established to Focus on Rare Diseases
Gemma Bio raised $34 million in a seed round led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital.
Stentix Awarded 2025 Y-Prize
Stentix won the 2025 Y-Prize competition after presenting their business plan for a bile duct stent that can be adjusted noninvasively to help patients maintain bile flow without further surgical inte
PCI’s 10th Anniversary Highlighted in Penn Today
PCI was featured as the lead story in the January 17th issue of Penn Today in recognition of its 10-year anniversary.
Innovating for Impact: Highlights from the Fall 2024 Penn I-Corps Cohort
Eight teams completed the program, and 26 individuals received valuable training in entrepreneurship.
Meet the 2024/2025 PCI Fellows Cohort
Eleven fellows were admitted to the 2023/2024 cohort out of a large application pool.
Penn’s Chief Innovation Officer John Swartley Interviewed by BioBuzz @ Philly Builds Bio+ Symposium and nominated for the Life Science Cares Leader of the Year Award
In the interview, Dr. Swartley talks about how he leads and supports innovation initiatives across Penn and his career in technology transfer.